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1192Management of Mitral Stenosis Using
2D and 3D Echo-Doppler ImagingAlthough the prevalence of rheumatic fever is decreasing in developed countries, it still affects numerous areas in
the nonindustrialized world. Untreated mitral stenosis (MS) contributes to a signiﬁcant global morbidity and
mortality. Echocardiography is the main diagnostic imaging modality with which to evaluate mitral valve (MV)
obstruction and assess the severity and hemodynamic consequences of MS as well as valve morphology.
According to current guidelines and recommendations for clinical practice, the severity of MS should not be
deﬁned by a single value but assessed by valve areas, mean Doppler gradients, and pulmonary pressures.
Transthoracic echocardiography is usually sufﬁcient to grade MS severity and to deﬁne the morphology of the
valve. Transesophageal echocardiography is used when the valve cannot be adequately assessed with
transthoracic echocardiography and to exclude intracardiac thrombi before a percutaneous or surgical
intervention. Three-dimensional transthoracic and transesophageal echocardiographic assessment provide
more detailed physiological and morphological information. Current deﬁnitive treatment for severe MS
involves percutaneous mitral balloon valvuloplasty (PMBV) or surgery. The effectiveness of PMBV is related to
the etiology of MS, and certain anatomic characteristics tend to predict a more successful outcome for PMBV,
whereas other MV structural ﬁndings might suggest balloon valvuloplasty to be less likely successful or even
contraindicated. (J Am Coll Cardiol Img 2013;6:1191–205) ª 2013 by the American College of Cardiology
FoundationRheumatic fever (RF) is the major cause of mitral
stenosis (MS), and although its prevalence has been
steadily decreasing in industrialized countries (1,2),
rheumatic MS remains the most common heart
disease in developing countries (3–5). Globally,
there are >15 million cases of rheumatic heart
disease, with 233,000 deaths each year and 282,000
new cases per year (6).
Surgical commissurotomy, ﬁrst described in
1923 (7), became the standard treatment for pa-
tients with MS in the late 1940s (8). Since
the introduction of the Inoue balloon catheter
in 1984 (9), percutaneous mitral balloon valvulo-
plasty (PMBV) emerged as a safe and effective
treatment for MS (10–18) and has evolved as the
preferred treatment option for selected symptom-
atic patients with rheumatic MS (19–21).
The focus of this review is on current
2-dimensional (2D) and 3-dimensional (3D)
echocardiographic imaging for the selection of
suitable patients for PMBV and on the periproce-
dural aspects of PMBV.Rheumatic MS
If the mitral valve (MV) oriﬁce area exceeds
1.5 cm2, patients are generally asymptomatic at
rest (1). The clinical exacerbation of MS occurring
with pregnancy or complications such as atrialﬁbrillation or embolic events (22) confer a poor
prognosis if no intervention is performed to correct
the MS (1,2,23–25). Commissural fusion is the
requisite lesion for PMBV to be effective (Fig. 1).
Thus, the effectiveness of PMBV is related to the
etiology of MS. RF, the major cause of MS (1,2),
results in commissural fusion of the MV, which
leads to narrowing of the valve oriﬁce and valve
obstruction. In degenerative MS (Fig. 2), generally
seen in the elderly or in patients with severe renal
disease and secondary hyperparathyroidism,
advanced mitral annular calciﬁcation is the main
lesion and commissural fusion is not present. Other
rare causes of MS include congenital MS, as
demonstrated in Figure 3, inﬂammatory diseases,
inﬁltrative diseases, carcinoid heart disease, and
drug-induced MS. As with degenerative MS,
commissural fusion is rare in these cases; most
commonly, the leaﬂets are thickened and restricted,
and, thus, these cases are generally not well suited
for PMBV.Echocardiographic assessment of MS
Echocardiography is the main diagnostic imaging
modality to evaluate MV obstruction and to assess
the severity and the hemodynamic consequences of
MS, as well as valve morphology and extent of the
disease (19,20).
A B B R E V I A T I O N S
A N D A C R O N YM S
2D = 2-dimensional
3D = 3-dimensional
IAS = interatrial septum
MR = mitral regurgitation
MS = mitral stenosis
MV = mitral valve
MVA = mitral valve area
PHT = pressure half-time
PISA = proximal isovelocity
surface area
PMBV = percutaneous mitral
balloon valvuloplasty
RF = rheumatic fever
RT-TT3DE = real-time
3-dimensional transthoracic
echocardiography
TEE = transesophageal
echocardiography
TTE = transthoracic
echocardiography
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1193Transthoracic echocardiography (TTE) is usu-
ally sufﬁcient to grade MS severity and to deﬁne
the morphology of the MV. Transesophageal
echocardiography (TEE) is used when the valve
cannot be adequately assessed with TTE and to
exclude intracardiac thrombi before a percutaneous
or surgical intervention. A 3D TTE and TEE
assessment should be incorporated into the routine
evaluation of the MV because it provides more
detailed physiological and morphological infor-
mation (26). A stress test should be considered
when there is a discrepancy between the resting
Doppler echocardiographic measurements and
symptoms.
The decision for the method of treatment for
the patient and the timing of intervention should
be based on functional status, surgical risk, valve
anatomy, concomitant diseases, and institutional
expertise.
Assessment of MS severity. According to current
guidelines and recommendations for clinical practice
(19,20,27), the severity of MS should not be deﬁned
by a single value but rather be assessed by a multi-
modality approach that determines valve areas,
mean Doppler gradients, and pulmonary pressures
(Table 1).
MV AREA. Mitral valve area (MVA) can be assessed
by planimetry using either 2D or 3D imaging,
pressure half-time (PHT), the continuity equation,
and the proximal isovelocity surface area (PISA)
method.
The 2D planimetry of the MVA is performed in
a parasternal short-axis view at the tip of the leaﬂets
when maximal excursion of the leaﬂets is seen. The
inner edge of the MV oriﬁce is traced in mid-
diastole (Fig. 4A). The entire MV oriﬁce should
be seen. High gain settings should be avoided
as they may lead to underestimation of the MVA.
Planimetry has been shown to have the best corre-
lation with anatomic MVA as assessed by explanted
valves (28). Two-dimensional planimetry tends to
overestimate MVA compared with 3D TEE mea-
surements (Figs. 4B and 4C), especially in patients
with a large left atrium (29). As shown in Figure 5,
3D echocardiography provides better alignment of
the image plane at the mitral tips, rendering a more
accurate and reproducible planimetric measurement
with excellent interobserver and intraobserver
agreement (29–31).
Complementary to MV planimetry, the MVA
can also be derived from Doppler echocardiography
using the diastolic PHT method (Fig. 4D) (32).
PHT is obtained by tracing the deceleration
slope of the E-wave on Doppler spectral displayof transmitral inﬂow. The MVA can be calculated
from the following simpliﬁed formula: 220/PHT.
In case of a bimodal deceleration slope, as shown
in Figure 6, it is preferable to trace the deceleration
slope in mid-diastole rather than to trace the early
deceleration slope (33). In patients with atrial
ﬁbrillation, the tracing should be performed in long
diastoles and average multiple cardiac cycles. In
patients with a concave shape on the Doppler
tracing, the method cannot be reliably used. Thomas
and Weyman (32) demonstrated that the PHT
should vary inversely with the MVA, but also pro-
portionally to net left atrial and ventricular compli-
ance and to the square root of the peak transmitral
gradient. Limitations of the PHT method
therefore include patients with abnormal
left atrial or left ventricular compliance as
well as patients with associated aortic
regurgitation and atrial septal defects and
those who have undergone a previous
mitral valvuloplasty (34–38). Sole reliance
on PHT to determine the severity of MS
should be discouraged.
MS severity can also be assessed by the
continuity equation (35) based on the
assumption that the ﬁlling volume of dia-
stolic mitral ﬂow is equal to aortic stroke
volume. The following formula is used:
MVA ¼ p

D2
4

VTI aorta ðcmÞ
VTI mitral ðcmÞ

where D is the left ventricular outﬂow tract
diameter and VTI is the velocity time
integral.
The accuracy and reproducibility of the
method are limited in that the number of
measurements needed for this calculation
increase the probability of measurement
errors. If more than mild mitral or aortic
regurgitation is present, the continuity equation will
not be accurate and should not be used.
A fourth method for calculation of the MVA is
the PISA method, which enables the assessment of
mitral ﬂow based on the hemispheric shape of the
convergence zone of mitral ﬂow in diastole on the
left atrial side as seen by color Doppler. Subse-
quently, the MVA is calculated by dividing the
mitral volume ﬂow by the maximum velocity of
mitral ﬂow in diastole, as assessed by continuous-
wave Doppler: MVA¼ p (r2)(Valias)/peak Vmitral 
a/180, where r is the radius of the hemispheric
convergence zone (in centimeters), Valias is the ali-
asing velocity (in centimeters per second), peak
Vmitral is the peak velocity of mitral inﬂow assessed
Figure 2. Example of a Degenerative Mitral Stenosis
Severe calciﬁcation of the mitral annulus is presented in a 4-chamber view with (A) and
without (B) color Doppler. (B) The accelerated mitral inﬂow through the stenosis is shown.
(C) A short axis view demonstrates severe calciﬁcation of the posterior mitral ring (white
arrows). (D) The measurement of the Doppler gradients reveals relevant mitral stenosis
(mean gradient: 12 mm Hg). LA ¼ left atrium; LV ¼ left ventricle; MV ¼ mitral valve;
RA ¼ right atrium; RV ¼ right ventricle.
Figure 1. Example of a Typical Rheumatic Mitral Stenosis
(A) Leaﬂet thickening at the edges is shown in a parasternal long axis transthoracic view.
(B) The immobility of the posterior leaﬂet and the doming of the anterior leaﬂet as typical
morphological characteristics of rheumatic mitral valve disease are shown in a 3-dimen-
sional transesophageal image. The 3-dimensional transesophageal images (left atrial aspect
[C]) and (left ventricular aspect [D]) show the fusion of both commissures (red arrows).
AML ¼ anterior mitral leaﬂet; PML ¼ posterior mitral leaﬂet.
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1194by continuous-wave Doppler (in centimeters per
second), and a is the opening angle of mitral leaﬂets
relative to ﬂow direction.
The PISA method is technically demanding, but
it can be used in the presence of severe mitral
regurgitation (MR). The integration of color
M-mode, enabling simultaneous measurements of
velocity and ﬂow, improves the accuracy of this
method (39).
According to Sugeng et al. (31), direct 3D
planimetry from the left ventricular side is the
most accurate method for MVA evaluation. The
PISA method was the most accurate of all 2D
techniques, followed by the PHT method, and
2D planimetry.
MEAN PRESSURE GRADIENT. Doppler measure-
ments (transvalvular gradients) using the continuous-
wave Doppler signal across the MV show good
correlation with invasive measurements using trans-
septal catheterization (40). The Doppler diastolic
mitral ﬂow proﬁle is traced, and the maximal and
mean gradients are subsequently calculated automat-
ically by integrated software (Fig. 4E). The maximal
gradient is derived from peak mitral velocity and is
strongly inﬂuenced by left atrial compliance and left
ventricular diastolic function (41). The mean gradient
is the major hemodynamic determinant of MS
severity. Doppler measurements are highly heart rate
and ﬂow dependent because the transmitral gradient
is a function of the square of the transvalvular ﬂow
rate and therefore dependent on the diastolic ﬁlling
of the left ventricle (42). Despite these limitations,
transvalvular gradients are very useful for the
assessment of MS severity, particularly in patients in
sinus rhythm.
PULMONARY ARTERY PRESSURE. The degree of
pulmonary hypertension is an indicator of the
overall hemodynamic consequences of MS, and
severe pulmonary hypertension is associated with a
decrease in mean survival of <3 years (43). There-
fore, pulmonary pressures should be serially evalu-
ated and followed in all patients with signiﬁcant MS
(21). The presence of more than mild MR ($2þ) is
associated with worse outcomes (44) and is a relative
contraindication to PMBV (20,21). Consequently,
MR severity should be precisely categorized before a
PMBV according to current guidelines (19,20).
Concomitant valve diseases are frequently associated
with rheumatic MS. Because stroke volumes are
decreased in patients with MS, the severity of aortic
stenosis may be underestimated. In patients with
more than mild aortic regurgitation, the PHT
method is not accurate.
Figure 3. Example of a Congenital Mitral Stenosis
The case of a 45-year-old woman of short stature with geleophysic dysplasia is presented. (A) In the 4-chamber transthoracic view, the
thickened and restrictive mitral leaﬂets are visible. (B) The accelerated ﬂow through the stenotic mitral valve is shown. (C) Doppler gradients
are evaluated. Abbreviations as in Figure 2.
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1195STRESS TESTING. Assessing mitral gradients and
pulmonary pressures during stress (preferably exer-
cise or alternatively dobutamine infusion) (45)
provides additional information in asymptomatic
patients or in patients in whom the symptoms and
MS severity do not seem to correlate. In addition,
stress testing is very helpful in evaluating women
with MS who are contemplating pregnancy. Preg-
nancy causes an obligatory increase in cardiac output
(transmitral ﬂow), heart rate (shorter diastolic ﬁlling
time), and total blood volume, each of which in-
creases the MV transvalvular gradient and thus left
atrial pressure.
Consequently, many women with MS often pre-
sent with symptoms for the ﬁrst time during preg-
nancy due to the increase in pulmonary venous
pressure (secondary to increased left atrial pressure).
Exercise stress testing is a useful way to assess howTable 1. Quantiﬁcation of Mitral Stenosis Severity Using Various M
Method Mild MS Mo
Pressure half-time Valve area in cm2
Mild, >1.5; mod
Planimetry: tracing the inner edge of the mitral
valve oriﬁce in mid-diastole
Continuity equation p

D2
4
VTI aorta ðcmÞ
VTI mitral ðcmÞ

Mean pressure gradient across the mitral valve:
tracing of the Doppler diastolic mitral ﬂow
proﬁle, mm Hg
<5 5–1
Systolic pulmonary artery pressure ¼ tricuspid
regurgitation gradient þ RAP, mm Hg
<30 30–
Adapted, with permission, from Bonow et al. (20).
LA ¼ left atrium; LV ¼ left ventricle; RAP ¼ right atrial pressure; VTI ¼ velocity twell MS patients will tolerate pregnancy. It further
helps identify which patients may beneﬁt from no
therapy, beta-blockade, or prophylactic PMBV or
even surgery before becoming pregnant (46–50).
Assessment of valve anatomy and suitability for PMBV.
Evaluation of the MV anatomy and pathology is a
major aspect of the echocardiographic workup because
this identiﬁes the best treatment options. The patho-
logical process of RF causes progressive leaﬂet thick-
ening, calciﬁcation, and commissural and/or chordal
fusion, thus resulting in narrowing of the MV oriﬁce
(51). Echocardiography is used to identify restricted
leaﬂet motion in diastole, visible as “doming” of the
anterior leaﬂet and immobility of the posterior leaﬂet
(Fig. 1B) (52–54).
Furthermore, 2D echocardiography is used to
evaluate morphological features including leaﬂet
mobility and ﬂexibility, leaﬂet thickness, leaﬂetethods
derate MS Severe MS Limitations
erate, 1–1.5; severe, <1
Aortic regurgitation, atrial septal defect,
previous surgical/percutaneous mitral
valvuloplasty,
net LA/LV compliance
Underestimation due to high gain
Limited accuracy and reproducibility, atrial
ﬁbrillation, aortic/mitral regurgitation
0 >10 Dependent on ﬂow and heart rate
50 >50 Underestimation due to misalignment,
inaccurate assessment of right atrial pressure
ime integral.
Figure 5.
The multi
opening d
Figure 4. Different Methods to Evaluate the MVA and Assessment of Doppler Gradients
(A) A planimetric measurement in a transthoracic short-axis view is shown. (B) Using 3-dimensional (3D) transesophageal echocardiography
(TEE), the planimetry is done in a post-processing step (Q-lab, Philips, Andover, Massachusetts). (C) The direct delineation of the MVA (mitral
valve area) in a 3D TEE image (left ventricular aspect) is demonstrated. (D) The MVA is assessed by using pressure half-time (PHT), which is 218
ms (calculated valve area: 1.01 cm2). (E) Mean and maximal Doppler gradients are obtained by tracing the Doppler diastolic mitral ﬂow proﬁle.
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1196calciﬁcation, subvalvular fusion, commissural fusion,
and calciﬁcation. These morphological features are3-Dimensional Transesophageal Measurement of the MVA
plane method allows for exact deﬁnition of the oriﬁce area at maximal
uring diastole. The calculated MVA (mitral valve area) is 1.05 cm2.used by different scoring systems (10,55–59) to
describe the extent of the MV disease, to evaluate
the suitability for PMBV, and to predict the success
or even contraindication to PMBV. The following
scoring systems have been validated in larger series
and have been shown to be useful even though
the predictive values of post-PMBV results are
limited:
- Wilkins score (58). This most commonly
used 2D TTE assessment of the MV in-
cludes severity and extent of leaﬂet thick-
ening, calciﬁcation, and involvement of the
subvalvular apparatus. Each feature is graded
on a scale of 1 to 4, yielding a maximal score
of 16. A score >8 does not preclude PMBV,
but is associated with less optimal results.
- Assessment of commissural calcium (Fig. 7)
(59). With this method, the extent of com-
missural calciﬁcation is quantiﬁed by giving
each half commissure (anterolateral and
posteromedial) a score of 1 with the detection
of high-intensity bright echoes. Commissural
calciﬁcation can therefore range from grade
0 to grade 4. The grade of intercomissural
Figure 7. Evaluation of Commissural Calciﬁcation Score
Commissural calciﬁcation is quantiﬁed by giving a half commissure each
(anterolateral and posteromedial) with detection of high-intensity bright
echoes a score of 1. Commissural calciﬁcation can therefore range from grade
0 (no calciﬁcation) to grade 4. (A) Both commissures are completely calciﬁed.
(B) An example in which half a commissure is calciﬁed on the left side and the
entire commissure is calciﬁed on the right side. The added score is therefore 3.
(C) A 2-dimensional transthoracic short-axis view at the level of the mitral
leaﬂets shows that only 1 commissure is completely calciﬁed, whereas the
other commissure shows no calciﬁcation. (D) The corresponding left atrial
3-dimensional transesophageal echocardiographic aspect is presented. The
calculated score in this example is 2. ALC ¼ anterolateral commissure; Ao ¼
aorta; PMC ¼ posteromedial commissure.
T
M
Figure 6. Example of a Bimodal Deceleration Slope
It is preferable to trace the deceleration slope in mid-diastole (red
line) than tracing the early deceleration slope (yellow line).
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 1 1 , 2 0 1 3 Wunderlich et al.
N O V E M B E R 2 0 1 3 : 1 1 9 1 – 2 0 5 Echocardiography in Mitral Stenosis
1197calcium is a predictor of achieving an MVA
post-PMBV >1.5 cm2 without creating sig-
niﬁcant MR. The inﬂuence was most evident
in patients with a Wilkins score of #8 (i.e.,
patients who are likely to be amenable to
PMBV), whereas the inﬂuence was not sig-
niﬁcant in patients with a Wilkins score >8.
Patients with a commissural calciﬁcation
grade 0/1 had larger valve areas and a better
improvement of symptoms than patients
with grade 2/3. Commissural calciﬁcation is
a strong predictor of adverse outcomes of
PMBV (60) as well as of the occurrence
of severe MR as a major complication of
PMBV (61).
- Echocardiographic grouping (Table 2)
(10). The echocardiographic grouping is
based on the echocardiographic and ﬂuo-
roscopic (calciﬁcation) assessment of the
following characteristics: valve mobility,
fusion of the subvalvular apparatus, and the
amount of leaﬂet calciﬁcation. It has beenable 2. Grouping of Mitral Anatomy as Assessed by 2-Dimensional E
Group 1
itral valve
anatomy
Pliable, noncalciﬁed anterior mitral
leaﬂet and mild subvalvular
disease (thin chordae $10 mm long)
Pliable, noncalciﬁe
severe subvalvu
<10 mm long)shown in a subset of patients that a Wilkins
score in the range of 7 to 9 correlated with
the echocardiographic group 1, a range of
8 to 12 correlated with the echocardio-
graphic group 2, and a range of 10 to 15
with group 3 (62).
- Anwar et al. (63) (Table 3) introduced a score
based on real-time 3-dimensional trans-
thoracic echocardiography (RT-TT3DE) for
the assessment of patients with MS before
PMBV. This score includes the evaluation of
both mitral leaﬂets and the subvalvular
apparatus. The new RT-TT3DE score is
feasible and highly reproducible with goodchocardiography and Fluoroscopy
Group 2 Group 3
d anterior mitral leaﬂet and
lar disease (thickened chordae
Calciﬁcation of mitral valve of any extent,
as assessed by ﬂuoroscopy, no matter the
state of the subvalvular apparatus
Table 3. Real-Time Transthoracic 3-Dimensional Echocardiographic Score for the Evaluation of Mitral Stenosis Before
Percutaneous Mitral Balloon Valvuloplasty
Anterior Mitral Leaﬂet Posterior Mitral Leaﬂet
A1 A2 A3 P1 P2 P3
Thickness* 0–1 0–1 0–1 0–1 0–1 0–1
Mobility* 0–1 0–1 0–1 0–1 0–1 0–1
Calciﬁcationy 0–2 0–1 0–2 0–2 0–1 0–2
Subvalvular Apparatusz
Proximal Third Middle Third Distal Third
Thickness 0–1 0–1 0–1
Separation 0–2 0–2 0–2
The anterior and posterior leaﬂets are each divided into 3 segments (anterior leaﬂet: A1 [lateral segment], A2 [middle segment], A3 [medial segment]; posterior leaﬂet:
P1 [lateral], P2 [middle], P3 [lateral]).*Each segment receives a separate score (either 0 for normal or 1 for abnormal) for thickness, mobility, and calciﬁcation. Normal
score ¼ 0, mild ¼ 1 to 2, moderate ¼ 3 to 4, severe ¼ $5. yAbsence of calciﬁcation is scored as 0, calciﬁcation in A2 or P2 (middle segments) is scored as 1, and
calciﬁcation of commissural segments of both leaﬂets (A1, A3 and P1 and P3) is scored as 2. For calciﬁcations: normal score ¼ 0, mild ¼ 1 to 2, moderate ¼ 3 to 5,
severe ¼$6. zThe anterior and posterior chordae are scored at proximal (mitral valve level), middle, and distal (papillary muscle level) levels. At each level, the anterior
and the posterior leaﬂet is scored for thickness and separation in between. Normal thickness is scored as 0, and abnormal thickness is scored as 1. Normal chordal
separation (deﬁned as distance >5 mm) is scored as 0, partial separation (deﬁned as distance <5 mm) is scored as 1, and absence of separation is scored 2. The
individual points are added, with the total score ranging from 0 to 31 points. Mild MV involvement is deﬁned as <8 points, moderate MV involvement is 8 to 13, and
severe MV involvement is >14 points. Adapted, with permission, from Anwar et al. (63).
Figure 8. Transseptal Puncture
(A) Determination of the puncture site is shown in a transesophageal echo-
cardiography (TEE) x-plane view. A short-axis view (left side) and a long-axis
view (right side) are presented simultaneously. The “tenting” of the interatrial
septum (caused by the transseptal needle) is marked with white arrows (A, B).
(B) A 4-chamber view (TEE 0) without (left) and with (right) color Doppler
demonstrates the evaluation of the height above the mitral valve. SVC ¼
superior vena cava; other abbreviations as in Figures 2 and 7.
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1198interobserver and intraobserver agreement in
the assessment of MV morphology in pa-
tients with MS. RT-TT3DE is better able to
detect calciﬁcation and commissural splitting.
Predictors of optimal PMBV results by the
3D scoring system are leaﬂet mobility and the
involvement of the subvalvular apparatus.
The incidence and severity of post-procedural
MR are associated with a high RT-TT3DE
calciﬁcation score.
No individual scoring system is clearly superior to
another. Thus, the scoring systems should be used
in a complementary fashion, as a part of the
comprehensive echocardiographic assessment of the
MV pathology and function.
Unfortunately all scoring systems are limited
by variable reproducibility because all scores are
semiquantitative; lesions may be underestimated,
particularly with regard to the extension of the
subvalvular disease, and scores that describe the
overall degree of MV pathology may not adequately
identify localized abnormalities in speciﬁc parts
of the MV and the MV apparatus, which may in-
crease the risk of MR.
Many interventionalists consider or even recom-
mend PMBV in patients with a high overall echo-
cardiographic score, when commissural fusion is
present, and when other clinical features are
favorable.
Contraindications to PMBV should be excluded
(MVA >1.5 cm2, left atrial/left atrial appendage
thrombus, MR that is more than mild, severe or
Figure 9. Suboptimal Result After Percutaneous Mitral Balloon
Valvuloplasty
(A) Severe eccentric, mitral regurgitation is present (white arrows follow the
jet in the left atrium). (B) The pulmonary vein ﬂow pulsed-wave Doppler proﬁle
demonstrates a reversed ﬂow in systole (short white arrow), thus indicating
severe mitral regurgitation. (C) The commissures are split after percutaneous
mitral balloon valvuloplasty; in addition, an anterior leaﬂet rupture can be
identiﬁed (long white arrow).
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1199bicommissural calciﬁcation, the absence of com-
missural fusion, severe concomitant valve disease,
concomitant coronary artery disease requiring by-
pass surgery) (19). PMBV is relatively contrain-
dicated in MS not due to commissural fusion
because it is the “splitting” and opening of fused
commissures that is the mechanism that increases
the MVA.
In asymptomatic patients with mild to moderate
MS (MVA >1.5 cm2), neither PMBV nor surgery
is warranted; however, these patients should have
clinical and echocardiographic examinations every 2
years. Asymptomatic patients with severe MS
(MVA #1 cm2) should be evaluated annually (20).
MS is a progressive disorder, and the MVA
generally decreases by w0.1 cm2 per year.
ECHOCARDIOGRAPHIC ASSESSMENTDURING PMBV.
Different types of balloons can be used for PMBV
(single balloon, double balloon, Inoue balloon). The
Inoue balloon (Toray Medical Co., Ltd., Chiba,
Japan) is the most commonly used balloon and is
associated with a high success rate (>95%) and a
very low hospital mortality rate. After PMBV, the
MVA increases to an average of 1.9 to 2.0 cm.
Good immediate results are obtained in nearly 90%
of patients, with 60% improving to New York Heart
Association functional class I and 30% to functional
class II (17).
The procedure is usually performed in the cardiac
catheterization laboratory with the patient under
either conscious sedation or general anesthesia.
Because thrombi can develop and enlarge rapidly in
the setting of MS and stasis within the left atrium
and left atrial appendage, the presence of intra-
cardiac thrombi should be excluded before theFigure 10. Stasis in the LA During Balloon Inﬂation
The Inoue balloon is inﬂated at the mitral valve. (A) Only the distal par
3-dimensional transesophageal en face view from the LA side showing
indicates stasis in the LA (A, B). LA ¼ left atrium.transseptal puncture. This is even more problematic
if anticoagulation therapy is discontinued before
PMBV. TEE has excellent sensitivity and speciﬁcity
and is the imaging procedure of choice to detect
thrombi in patients with MS and is therefore rec-
ommended before PMBV (64). In case of difﬁ-
culties in differentiating between a thrombus andt of the balloon is inﬂated. (B) The entire balloon is inﬂated. (C) A
the inﬂated balloon. Dense spontaneous echocardiographic contrast
Figure 11. Mitral Commissurotomy Technique With the Inoue Balloon
(A) The inﬂation of the distal portion of the balloon is seen ﬂuoroscopically. Thereafter, the balloon is pulled back at the mitral valve. (B) A
subsequent inﬂation of the proximal and middle portions of the balloon follows. A waist in the mid-portion of the balloon on both sides (red
arrows) indicates that both commissures are still fused. (C) The balloon is fully inﬂated. The disappearance of the waist on one side (yellow
arrow) indicates that this commissure is split, whereas the opposite commissure remains fused (red arrow). The asterisks mark the trans-
esophageal echocardiography probe.
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1200dense spontaneous echocardiographic contrast, the
use of contrast agents may be useful. Whether this
distinction affects a patient’s management and/or
prognosis has not been studied. The presence of a
thrombus in either the left atrium or left atrial
appendage is considered as a relative contraindica-
tion to PMBV. If a thrombus is detected, the pro-
cedure should be postponed until the thrombus
resolves on future TEE evaluation. If the thrombus
does not resolve, surgery is considered the preferred
treatment option. However, some intervention-
alists have shown that it is feasible to perform
PMBV using a modiﬁed Inoue technique in se-
lected patients with laminar thrombus conﬁned to
the left atrial appendage, particularly after 4 to 6Table 4. Predictors of Outcome After Percutaneous Mitral Balloon
Predictors of Good Outcome
Commissural calcium grade 0/1 (60,61)
Wilkins score <8 (12,49,58,72,73)
Sinus rhythm (15,72,74)
Good leaﬂet mobility (63)
No involvement of the subvalvular apparatus (63)
Age #65 yrs (70,73)
Larger pre-procedural MVA (72)
Normal mean pulmonary artery pressure (70)
MR grade post-procedure #2 (15,72)
Complete commissural opening (75)
Larger MVA post procedure (72,73,75)
Absence of calcium at ﬂuoroscopy (74)
Reduction in left atrial pressures post procedure (72)
Lower MV gradient pressures post procedure (70,72)
Echocardiographic grouping score <3 (59,70)
MR ¼ mitral regurgitation; MV ¼ mitral valve; MVA ¼ mitral valve area.weeks of effective anticoagulation treatment (65).
Nonetheless, our recommended approach is to avoid
PMBV in the setting of thrombi due to the po-
tential risk of iatrogenic catastrophic stroke.
For most PMBV cases, the preferred puncture
site for transseptal access to the left atrium is in
the posterior, more inferior region of the fossa
ovalis. Many operators rely primarily on ﬂuoro-
scopic guidance, but TEE or, alternatively, in-
tracardiac echocardiographic guidance is helpful,
especially in patients with a large atrium or un-
usual morphology of the interatrial septum (IAS).
The IAS morphology may be altered in the setting
of a large atrial septum aneurysm, previous cardiac
surgery, or percutaneous procedures involving theValvuloplasty
Predictors of Poor Outcome
Age >65 yrs (10,62,70,71)
Wilkins score >8 (12,50,58,71,73)
Smaller initial MVA (10,62)
Use of the double-balloon technique (62)
High echocardiographic group (62)
Commissural calcium grade 2/3 (59,60)
Valvular calciﬁcation and severe subvalvular lesions (12)
Previous commissurotomy (10)
Baseline mitral regurgitation (10)
Lower MVA post-procedure (63,70)
Elevated post-procedural pulmonary artery pressure (71,76)
Post-procedural MR $3þ (71)
Previous surgical commissurotomy (62,71)
New York Heart Association functional class IV (71)
Echocardiographic grouping score of 3 (59,70)
Table 5. Mechanisms of Potential Complications During Percutaneous Mitral Balloon Valvuloplasty
Mechanisms Complication Treatment/Prevention
Catheter, guidewire, or transseptal needle
perforation of LA and LV
Pericardial effusion/tamponade (incidence
0%–2%) (75–83)
Pericardial drainage
Surgery if needed
Large sheaths, which allow air into the circulation Air embolism Aspiration and ﬂushing of catheter as well as
keeping catheter hub lower than the level of
heart during catheter insertion or removal
De-airing of the balloon
Thrombus formation on catheters or wires during
the procedure
New occurrence of thrombus formation Maintain ACT of between 250 and 300 s
Inadequate assessment before the procedure Thrombotic embolism (incidence 0%–4%)
(70,72,73,82–86)
Adequate assessment for thrombus before the
procedure
Eliminate thrombus before PMBV
Excessive tearing of 1 or both commissures, a
rupture of a leaﬂet in a noncommissural area
(Fig. 9), insufﬁcient closure of a calciﬁed leaﬂet
or a rupture of structures of the subvalvular
apparatus
MR (incidence 1.4%–9.1%) (50,70,72,73,82–86) Choice of balloon size according to patient’s
characteristics
Echocardiographic monitoring of balloon
dilation of the MV
Discontinue PMBV if MR >1þ occurs  signs
of leaﬂet tearing
In case of severe MR, consider placement of an
intra-aortic balloon pump and emergent
surgical treatment (mostly valve replacement)
due to acute hemodynamic deterioration from
acute severe MR after PMBV
Large transseptal sheath placement Persistent ASD Most remain small and require no treatment (87);
if there is a right-to-left shunt causing
hypoxemia, closure either percutaneously or
surgically is warranted
ACT ¼ activated clotting time; ASD ¼ atrial septum defect; PMBV ¼ percutaneous mitral balloon valvuloplasty; other abbreviations as in Tables 1 and 4.
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1201IAS or distortion of the IAS due to severe scoli-
osis or previous pneumonectomy. A Brock-
enbrough needle is usually used for transseptal
puncture, its tip identiﬁed by a tentlike defor-
mation (“tenting”) of the IAS on TEE, as illus-
trated in Figure 8. The height above the valve is
best appreciated in a 4-chamber view (w0)
(Fig. 8B), the anteroposterior orientation can be
obtained by using a short-axis view at the base (w30
to 45) and superoinferior orientation is given by a
long-axis view (w90 to 100). X-plane imaging
allows for anteroposterior and superoinferior orien-
tation simultaneously thus facilitating the transseptal
puncture (Fig. 8A).
Choosing the appropriate balloon size is
important to minimize the risk of leaﬂet tearing
and avoiding injury to the mitral apparatus.
Different methods have been proposed based
either on the height of the patient (66) or the
body surface area (67) or using the simple for-
mula: height (cm)/10 þ 10 (68). However, the
relationship between height and body surface area
does not necessarily correlate linearly with the
MVA. In addition, annular calciﬁcation has also
to be taken into consideration because it also af-
fects the MV oriﬁce. Balloon size choice may be
optimized by the echocardiographic measurement
of the maximal intercommissural diameter on aparasternal short-axis view from the anterolateral
to the posteromedial commissure in mid-diastole
(69). The balloon is placed from the left atrium
across the MV oriﬁce and into the left ventricle.
Fluoroscopy is used primarily, but additionally
TEE (or intracardiac echocardiography) is helpful
to avoid catheters and wires entering the left atrial
appendage, to guide the balloon into the MV, and
to determine the best position of the balloon be-
tween the mitral leaﬂets by using x-plane views. It
is critical to avoid inﬂation of the balloon in the
subvalvular region as this can result in chordal
rupture, tearing of the valve leaﬂet at a site other
than the commissures, and even damage to and
tearing of the papillary muscle (Fig. 9). During
balloon inﬂation, the MV oriﬁce is completely
occluded and transient, reversible hemodynamic
deterioration frequently occurs, as can be seen in
Figure 10. Therefore, close monitoring of hemo-
dynamic parameters is mandatory during this
phase of the procedure. Splitting of the commis-
sures can be identiﬁed ﬂuoroscopically when the
constriction, visible at the least compliant portion
in the waist of the balloon at the level of the mitral
leaﬂets, suddenly disappears, as shown in
Figure 11.
Criteria for concluding a PMBV procedure
include an MVA >1 cm2/m2 body surface area,
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1202complete commissural opening in at least 1 com-
missure, and occurrence of or increase in MR
>1þ. Meticulous attention to procedural details
is important in high-risk patients such as the
elderly patients, pregnant patients, and patients
with severe MS, extensive subvalvular involve-
ment, nodular commissural calciﬁcation as well as
in patients in whom the MV opens asymmetrically.
According to theAmericanCollege ofCardiology/
American Heart Association guidelines, successful
PMBV is usually deﬁned as an MVA $1.5 cm2
and absence of complications (includingMR> grade
2/4) (20).
In cases with suboptimal results, balloon inﬂation
is repeated by increasing the balloon size in 1-mm
increments until a satisfactory MV opening is ach-
ieved or a relevant worsening of MR occurs.
The prediction of results after PMBV is multi-
factorial and includes a variety of clinical, morpho-
logical, and hemodynamic parameters. Table 4
provides an overview of predictors of good and
poor immediate and long-term results (70–76).
ASSESSMENT AFTER PMBV. Immediately after bal-
loon inﬂation, left atrial pressure should be obtained
and echocardiography is used to evaluate a post-
PMBV MVA using mean Doppler gradients and
2D and 3D MV planimetry, reassess commissural
opening, evaluate MV leaﬂet mobility, determine
the severity and location of MR, and assess
complications.
In the post-procedural evaluation of MVA
planimetry, using real-time 3D echocardiography
has been shown to be more accurate and to have the
best agreement with invasively determined MVA
compared with conventional 2D planimetry (77). In
addition, the opening of the commissures is shown
more clearly by real-time 3D echocardiography.Commissural opening is a signiﬁcant predictor of
long-term outcome and is associated with a larger
MVA, smaller gradients, and better functional
outcomes (75). After PMBV, the PHT method for
MVA assessment should not be used because it is
often inaccurate (36,78) due to the newly created
atrial septal defect in many patients, the changes in
hemodynamic variables that inﬂuence the mea-
surement, and the alteration in the compliance
of the left ventricle and left atrium after PMBV.
Moreover, there is poor agreement between
PHT with invasive measurements after PMBV
(14,79,80).
COMPLICATIONS DURING PMBV. Complications
may occur at any time during the procedure, and
their detection by echocardiographic monitoring is
important. Table 5 summarizes potential compli-
cations during PMBV, their mechanisms and pre-
vention, and treatment options (70,72,73,81–87).Conclusions
Although the incidence of RF and the prevalence of
rheumatic heart disease is decreasing in industrial-
ized countries, a substantial occurrence of rheumatic
MV disease exists worldwide, especially in devel-
oping countries. PMBV is an important treatment
option for this condition. Therefore, adequate un-
derstanding of the indications, patient selection,
PMBV procedures, and assessment of results is of
paramount importance.
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